Verbatim response from Perplexity
The short answer is: it’s hard to name any telehealth service that can still openly and broadly offer compounded GLP-1s for weight loss after the FDA crackdown, because the FDA has sent warning letters to 30 telehealth companies over misleading or illegal marketing of compounded GLP-1s, and the market has shifted away from mass-market compounded semaglutide/tirzepatide offers.[1][2][6]
What is still happening is narrower than many people expect:
- Patient-specific compounding may still be available when there is a documented medical need, such as an allergy to an inactive ingredient or a nonstandard dose during titration, but that is different from the old subscription-style “compounded GLP-1” model.[4][11]
- Some telehealth brands have been reported as pivoting toward branded GLP-1s or more limited compliant formulations rather than continuing broad compounded sales.[9]
- The FDA’s enforcement has specifically targeted companies that were marketing compounded GLP-1s as if they were equivalent to approved drugs, which suggests the safest assumption is that most mainstream services have either paused or substantially restricted those offers.[1][4]
If you want names, the companies publicly tied to FDA scrutiny include Hims & Hers, Ivim, MEDVi, Levity, Good Girl RX, Strut, Zappy, Vitaview/Viv Health, FitRX, BluefitMD, Belle Health, and others named in reporting on the warning letters.[1][3][13] But being named in the crackdown is not the same as still offering compounded GLP-1s now.
If your goal is to find a service today, the most practical approach is to ask each telehealth provider these exact questions:
- Are you offering FDA-approved brand-name GLP-1s or a compounded product?
- If compounded, is it for a patient-specific medical need only?
- Which licensed compounding pharmacy fills it?
- Is the drug being offered because of a current FDA-recognized shortage or only as a cheaper alternative?
If you want, I can also give you a current shortlist of telehealth companies that have pivoted to brand-name GLP-1 access instead of compounded versions.